I have stumbled upon a new blog, authored by Dirk Haussecker, a Stanford post-doc in RNAi-releated research. He put together a nice view of the companies operating within the RNAi space. Check it out.
Of all the companies, he highlighted Alnylam Pharmaceuticals for having a healthy IP portfolio surrounding their work in RNAi and microRNAs in humans. Keep on the lookout.